Guggenheim analyst Michael Schmidt downgraded ImmunoGen (IMGN) to Neutral from Buy with a price target of $31, up from $25, after the company agreed to be acquired by AbbVie (ABBV) for $31.26 per share in cash.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
